Churchyard, Gavin

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

Boeree, M. J., Heinrich, N., Aarnoutse, R., Diacon, A. H., Dawson, R., Rehal, S., Kibiki, G. S., Churchyard, G., Sanne, I., Ntinginya, N. E., et al. (2017) · The Lancet Infectious Diseases

Tuberculosis Research and EpidemiologyInfectious Diseases and Tuberculosis

Cited by 379

A Trial of Mass Isoniazid Preventive Therapy for Tuberculosis Control

Churchyard, G. J., Fielding, K. L., Lewis, J. J., Coetzee, L., Corbett, E. L., Godfrey-Faussett, P., Hayes, R. J., Chaisson, R. E., & Grant, A. D. (2014) · New England Journal of Medicine

Tuberculosis Research and EpidemiologyHIV, TB, and STIs Epidemiology

Cited by 238

Tuberculosis Vaccines and Prevention of Infection

Hawn, T. R., Day, T. A., Scriba, T. J., Hatherill, M., Hanekom, W. A., Evans, T. G., Churchyard, G. J., Kublin, J. G., Bekker, L.-G., & Self, S. G. (2014) · Microbiology and Molecular Biology Reviews

Tuberculosis Research and EpidemiologyImmune responses and vaccinations

Cited by 164

Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis

Reid, M., Agbassi, Y. J. P., Arinaminpathy, N., Bercasio, A., Bhargava, A., Bhargava, M., Bloom, A., Cattamanchi, A., Chaisson, R., Chin, D., et al. (2023) · The Lancet

Tuberculosis Research and EpidemiologyInfectious Diseases and Tuberculosis

Cited by 87